Psilocybin for alcohol addiction is the most studied psychedelic application for substance use disorder, and the data is unusually strong. In a 2022 Phase 2 randomized trial published in JAMA Psychiatry, two psilocybin sessions combined with twelve weeks of psychotherapy produced an 83 percent reduction in heavy drinking days at the 32-week follow-up, compared to 51 percent in the active placebo arm (Bogenschutz et al., JAMA Psychiatry, 2022). The sample was 95 adults meeting DSM-5 criteria for alcohol use disorder. The effect was sustained, not transient. The integration scaffolding around the sessions was as much a part of the protocol as the substance.

That last point is what gets lost when the result moves into general coverage. The headline number is the drug effect. The durable change is the drug plus the structured therapeutic container that the trial built around it. Pulling out the substance and ignoring the scaffolding is one of the more common ways the work goes wrong in the wild. For the broader context of how this kind of work fits into stress and recovery, see psychedelics for burnout, since high-functioning alcohol use sits on top of burnout more often than not.

The question I want to address is narrow. What did the JAMA trial actually show, what is the proposed neurobiological mechanism, how does this compare to the two FDA-approved medications for alcohol use disorder, and what does an integration framework look like that respects the high-functioning executive case the trial only partially captured. The honest answer is more useful than the optimistic one.

Key Takeaways
  • The Bogenschutz 2022 JAMA Psychiatry trial (n=95) reported an 83 percent reduction in heavy drinking days with psilocybin plus therapy versus 51 percent with active placebo plus therapy, sustained at 32-week follow-up.
  • Acamprosate and naltrexone, the two FDA-approved medications for AUD, produce roughly 40 to 50 percent reductions in heavy drinking in Cochrane meta-analyses, with only 30 to 50 percent of patients responding.
  • The proposed mechanism involves 5-HT2A receptor agonism, default mode network suppression, and a 2-to-4 week BDNF plasticity window that supports behavioral and identity-level change.
  • The trial population was mostly white and college-educated, which overlaps with the founder and executive demographic but does not automatically generalize to all AUD presentations.
  • The DSM-5 AUD criteria and the AUDIT screening tool tend to miss high-functioning drinkers because they emphasize functional impairment that successful executives have not yet shown.
  • Active heavy drinking and unmedicated detox are contraindications. Medically supervised stabilization before psychedelic-assisted work is non-negotiable.

What Did the 2022 JAMA Psychiatry Trial Actually Show?

Bogenschutz and colleagues randomized 95 adults with DSM-5 alcohol use disorder to either two psilocybin sessions or two active placebo sessions (diphenhydramine), with both arms receiving twelve weeks of structured psychotherapy (JAMA Psychiatry, 2022). At the 32-week follow-up, the psilocybin arm showed an 83 percent reduction in heavy drinking days compared to baseline. The active placebo arm, with the same therapy, showed a 51 percent reduction. The 32-percentage-point gap is the drug effect, sitting on top of a therapy-only effect that was itself non-trivial.

Several details matter for reading the result correctly. The therapy was twelve weeks of structured Motivational Enhancement Therapy and CBT, not a casual integration chat. Both arms received it. The active placebo (diphenhydramine, an antihistamine that produces sedation) was chosen specifically to blind participants to which arm they were in, since pure inert placebo would be transparently identifiable. The follow-up window of 32 weeks is unusually long for an addiction trial. Most pharmacotherapy studies report shorter durations.

What the Numbers Mean in Plain Language

An 83 percent reduction in heavy drinking days does not mean total abstinence in 83 percent of participants. It means that across the group, the number of days per month on which participants drank above the heavy-drinking threshold (five or more standard drinks for men, four or more for women, per NIAAA criteria) dropped by 83 percent compared to where they started. Some participants achieved complete abstinence. Others moved from daily heavy drinking to occasional heavy drinking. The change was meaningful at the group level and sustained across the follow-up window.

Bogenschutz and colleagues (JAMA Psychiatry, 2022, n=95 in a Phase 2 double-blind randomized clinical trial) reported that two psilocybin sessions (25 mg/70 kg and then a second dose of 25 to 40 mg/70 kg) combined with twelve weeks of Motivational Enhancement Therapy produced an 83 percent reduction in heavy drinking days at the 32-week follow-up, compared to 51 percent in the diphenhydramine active-placebo arm receiving the same therapy. The trial is the largest psychedelic addiction RCT to date and represents a substantially larger effect size than the FDA-approved pharmacotherapies acamprosate and naltrexone show in Cochrane meta-analyses, though the population was predominantly white and college-educated.

Earlier Open-Label Data

The 2022 RCT was preceded by an open-label proof-of-concept study from the same group in 2015 (Bogenschutz et al., Journal of Psychopharmacology, 2015), in which 10 participants with active alcohol dependence received two psilocybin sessions and showed significant reductions in drinking that persisted at the 36-week follow-up. The 2022 trial was the larger, controlled confirmation of the earlier signal. Both used a similar therapeutic structure built around the sessions, which is consistent with the broader literature finding that the integration container is a substantial part of what produces durable change.

How Does Psilocybin Act on the Drinking Brain?

Psilocybin produces its effects through 5-HT2A receptor agonism on cortical pyramidal neurons, with downstream consequences for default mode network connectivity and BDNF-mediated synaptic plasticity, according to mechanism reviews in the psychedelic literature. For alcohol use disorder specifically, the proposed pathway involves three converging effects in the same post-session window: acute DMN suppression that loosens rigid self-narratives, a 2-to-4 week plasticity window that supports new behavioral patterns, and a subjective meaning-making process that reframes the drinking pattern itself.

DMN Suppression and the Self-as-Drinker Identity

In long-term alcohol use disorder, drinking is rarely just a behavior. It is woven into an identity. The default mode network is the set of brain regions that maintains the self-narrative across time. In active addiction, the DMN tends to rehearse the self-as-drinker continuously, which is part of why willpower-based attempts to stop typically fail. Psilocybin produces dose-dependent DMN suppression during the acute experience, with measurable reductions in pathological DMN hyperconnectivity sustained at follow-up. The identity loosens. The person can experience themselves outside the drinking pattern in a way that has not been available for years.

The BDNF Plasticity Window

BDNF, brain-derived neurotrophic factor, supports the formation of new synaptic connections. Psilocybin produces a BDNF and TrkB signaling cascade that peaks in days one through fourteen post-session and subsides by week four. This is the structural window for behavioral change. New patterns of attention, new responses to drinking cues, and new replacement behaviors formed during this period have biological support that is not present at baseline. This mechanism is consistent across psilocybin applications and is one reason the same compound shows effects in depression, smoking cessation, and AUD.

Meaning-Making About the Drinking Pattern

The third component is harder to quantify but consistent across the qualitative data. Participants in the Bogenschutz trials reported insight during sessions about what their drinking had been doing for them emotionally, what it had been substituting for, and what its actual cost had been. This is not mystical. It is what the DMN suppression and acute neuroplasticity make possible: the rigid story about the drinking loosens enough to be examined, and the examination tends to produce a different felt relationship with the substance. This is also why integration matters. The insight without the structural follow-through tends to regress within months.

83%
reduction in heavy drinking days at 32-week follow-up after two psilocybin sessions plus twelve weeks of therapy, versus 51 percent with active placebo plus the same therapy
Bogenschutz et al., JAMA Psychiatry, 2022 (n=95)

How Does Psilocybin Compare to Acamprosate and Naltrexone?

Acamprosate and naltrexone, the two FDA-approved oral medications for alcohol use disorder, produce roughly 40 to 50 percent reductions in heavy drinking days and only about 30 to 50 percent of patients respond meaningfully, according to Cochrane meta-analyses on each compound. The Bogenschutz psilocybin effect of 83 percent reduction is substantially larger, and the dosing schedule is dramatically lower, two sessions over twelve weeks rather than daily medication for months or years. The comparison is not apples to apples, but the difference is large enough to be clinically meaningful.

Naltrexone: Targeting the Reward Loop

Naltrexone is an opioid receptor antagonist. It blunts the reward response to alcohol, making drinking less rewarding without preventing it. Cochrane reviews place its effect size in the small-to-moderate range, with daily oral dosing producing roughly 30 to 50 percent response rates. Adherence is the chronic problem. Daily dosing for an indefinite duration is difficult to sustain, and discontinuation typically produces a return to baseline drinking patterns. The mechanism is symptomatic rather than structural: it modifies the reward response without addressing the conditions that drove the drinking.

Acamprosate: Stabilizing Glutamate

Acamprosate modulates glutamate and GABA signaling that has been chronically dysregulated by alcohol. It is most useful in the post-detox period for maintaining abstinence, with Cochrane data showing modest effects on continuous abstinence rates. Like naltrexone, it requires sustained daily dosing and addresses neurochemistry rather than the behavioral and identity layers. Neither medication has been shown to produce the kind of durable, structural change that the Bogenschutz trial reported at 32 weeks following only two sessions.

Why the Comparison Is Not Quite Fair

The honest caveat is that the trials are not directly comparable. The psilocybin study included twelve weeks of structured psychotherapy that the typical naltrexone or acamprosate prescription does not. The therapy alone produced a 51 percent reduction in heavy drinking days, comparable to the medication effects. The psilocybin added another 32 percentage points on top of that. So the relevant comparison is not "psilocybin vs naltrexone" but "psilocybin plus therapy vs medication plus typical care." The first combination still appears more effective, but the magnitude of difference shrinks when the comparison is properly structured.

The World Health Organization estimates 283 million adults globally have an alcohol use disorder (WHO Global Status Report on Alcohol, 2024), making it the most common substance dependence by absolute prevalence. Standard pharmacological options, naltrexone and acamprosate, show modest effect sizes in Cochrane meta-analyses: naltrexone reduces relapse risk by 17 percent (Jonas et al., 2014, JAMA), acamprosate increases abstinence days by approximately 11 percent (Rosner et al., 2010, Cochrane Database). Both are useful but incremental. Psilocybin's 32 percent absolute reduction in heavy drinking days over placebo (Bogenschutz 2022) represents an effect size 2 to 3 times larger than current first-line pharmacology, which is why the field considers this Phase 2 result clinically significant rather than statistically incremental.

51%
Placebo arm reduction in heavy drinking days in the Bogenschutz 2022 trial, showing that even structured therapy without psilocybin produces meaningful change. The 83 percent in the psilocybin arm is the increment over an already-effective foundation.
Bogenschutz et al., JAMA Psychiatry, 2022 (n=95)

Why Do High-Functioning Executive Drinkers Get Missed?

The DSM-5 criteria for alcohol use disorder and the AUDIT screening tool both emphasize functional impairment that successful executives often have not yet shown, which is one reason high-functioning drinkers are systematically under-identified in clinical settings. The Bogenschutz 2022 trial population was mostly white, college-educated, and recruited from urban academic medical centers, demographics that overlap with the founder and executive population but with a key difference: the trial participants had already screened in. The high-functioning case typically does not.

The DSM-5 lists eleven criteria for AUD. A diagnosis requires at least two within a twelve-month period. Several of the criteria, things like failure to fulfill major obligations, recurrent legal problems, social withdrawal, or use in physically hazardous situations, are exactly the markers that a high-functioning drinker has structured their life to avoid. The executive who drinks a bottle of wine alone at home four nights a week, performs well at work, maintains relationships, and never drives drunk can meet only one or two criteria for years before the pattern becomes clinically visible. By the time it does, the underlying liver damage, the cognitive cost, and the behavioral entrenchment are substantial.

The Founder Pattern Specifically

In clinical work with founders post-retreat, the high-functioning drinking pattern shows up reliably and looks roughly like this: the drinking started as a way to decompress from chronic work stress, escalated during a particularly intense growth or fundraising period, and then stabilized at a level that exceeds national heavy-drinking thresholds but stays below what would force a confrontation. The person often does not consider themselves an alcoholic. They consider themselves a high performer who happens to drink more than is ideal. The framing protects the pattern from intervention.

What I observed in retreat settings is that this presentation responds well to psilocybin-assisted work when the integration framework explicitly addresses the work-stress driver, not just the drinking. The drinking is downstream of the load. Removing the drinking without addressing what the drinking was doing tends to produce relapse or symptom substitution, often into stimulants or compulsive working. The most durable outcomes I saw involved a structural change in the work pattern alongside the psychedelic intervention. For the broader founder-specific framework that this kind of integration sits inside, see psychedelics for entrepreneurs.

"The drinking is rarely the problem. It is the solution to a problem the person has not yet named. Psilocybin can let them name it. Integration is whether they let the named thing actually change."

A quiet morning workspace with a coffee cup and notebook in soft natural light, suggesting the post-session integration period when new behavioral patterns can consolidate during the BDNF plasticity window.
The two-to-four-week window after a psilocybin session is when new patterns have the most biological support. Returning into the same work stress that drove the drinking tends to consume the window without producing change.

What Does Integration That Actually Holds Look Like?

A serious integration framework for AUD recovery has three layers that most retreat programs skip: behavioral consolidation during the 2-to-4 week BDNF window, identity-level work on what the drinking was substituting for, and structural change in the load conditions that drove the pattern, with relapse prevention research from Bowen and colleagues (JAMA Psychiatry, 2014) showing that mindfulness-based relapse prevention outperforms standard relapse prevention at 12-month follow-up. The psilocybin session is necessary. It is not sufficient. The structure around it determines whether anything holds.

The First Two Weeks: Behavioral Consolidation

The post-session window is when new responses to drinking cues, new replacement behaviors, and new boundaries around the drinking environment have the most biological support. This is the period to do the work that would otherwise feel impossible: pour out the bar at home, alter the social schedule that revolved around drinking, build the new evening routine that does not include alcohol. The plasticity window will close. The question is what patterns have been laid down before it does. For the body-level dimension of this work, see somatic psychedelic integration.

Weeks Two Through Eight: Identity Reconstruction

The DMN suppression and meaning-making during the session typically surface what the drinking has been doing emotionally: numbing, decompressing, marking the boundary between work and home, providing a structured way to feel something. Integration is the slower work of building those functions back through means other than alcohol. This is where therapy, somatic practice, and structured reflection do the heaviest lifting. The drinking-as-identity loosens during the session. The new identity is constructed afterward, deliberately. For the broader integration framework, see psychedelic integration therapy.

Months Two Through Six: Structural Change

The hardest part of AUD integration for high-functioning drinkers is structural. The session can show a founder, with unusual clarity, that the way they are running their work life produced the conditions in which the drinking made sense. Integration is whether they change those conditions. The redesigned calendar, the renegotiated leadership role, the actual rest that has been deferred for years, these are the structural integration. Without them, the insight regresses and the drinking returns, often within six to nine months.

Bowen and colleagues (JAMA Psychiatry, 2014, n=286 in a randomized clinical trial) compared mindfulness-based relapse prevention to standard cognitive-behavioral relapse prevention and to treatment as usual for substance use disorders, finding that the mindfulness-based approach showed superior outcomes at 12-month follow-up, particularly for heavy drinking and drug use days. The result is relevant to psilocybin AUD work because the post-session integration period appears to amplify mindfulness-based interventions in the same way it amplifies behavioral change generally, with the plasticity window providing biological support for the practices to consolidate, and because relapse prevention research consistently identifies the period from weeks four through twenty-four as the highest-risk window for return to use.

The pre-session preparation framework also matters here. The session does not happen in isolation. For the protocol that I use with founders working on alcohol patterns specifically, see psilocybin therapy preparation.

What Are the Risks and Honest Caveats?

The Bogenschutz trial excluded participants with bipolar disorder, psychotic disorders, severe medical comorbidity, and recent unmedicated alcohol withdrawal, which means the safety profile of the trial does not automatically generalize to people with those conditions. According to the WHO Global Status Report on Alcohol and Health, alcohol use disorder affects roughly 283 million adults worldwide and contributes to over three million deaths annually (WHO, 2024), which makes the safe expansion of treatment options a meaningful public health question, but the safety screening in the original trial was strict for a reason.

Active Drinking and Detox Risk

Two contraindications are absolute. Active heavy drinking interferes with neurotransmitter systems in ways that increase the risk of dysregulated arousal during a psychedelic session. Recent unmedicated alcohol detox carries seizure risk that does not mix safely with the autonomic activation of a psychedelic experience. Both require medical management before any psychedelic work is appropriate. A structured taper, supervised detox where indicated, and a baseline of stable reduced use or abstinence are prerequisites, not options.

Psychiatric Comorbidity

The trial excluded bipolar disorder and primary psychotic disorders for established reasons related to psychedelic risk in those populations. AUD frequently co-occurs with depression, anxiety, and trauma-related conditions, and the psilocybin work can be useful for these comorbidities, but the screening needs to be careful. A history of psychotic features, family history of psychosis, or active suicidality is a stop sign rather than a complication to work around.

The Generalization Problem

The Bogenschutz sample was mostly white, college-educated, and psychiatrically stable. The 83 percent reduction in heavy drinking days is the result in that population, with that therapy, in that controlled setting. The result does not automatically transfer to underground retreat use, to populations with different comorbidity profiles, or to interventions without the twelve weeks of structured therapy. The signal is real and the mechanism is plausible, but the clinical extrapolation needs to be made carefully. This is also why working with founders post-retreat often involves more remediation than ideal: the substance was used, the scaffolding was not.

Frequently Asked Questions

In the Bogenschutz 2022 JAMA Psychiatry Phase 2 randomized trial (n=95), two psilocybin sessions combined with twelve weeks of psychotherapy produced an 83 percent reduction in heavy drinking days at the 32-week follow-up, compared to 51 percent in the active placebo arm that also received the therapy. For context, acamprosate and naltrexone, the two FDA-approved medications for alcohol use disorder, produce roughly 40 to 50 percent reductions in heavy drinking days in Cochrane meta-analyses, and only about 30 to 50 percent of patients respond to them at all. Psilocybin's effect size is larger and the dosing schedule is dramatically lower, two sessions rather than daily medication. The catch is that the trial population was mostly white, college-educated, and screened for psychiatric stability, so the result does not automatically generalize to all AUD presentations.
The Bogenschutz 2022 sample was predominantly white, college-educated, and recruited from urban academic medical centers, which overlaps demographically with the high-functioning executive population, but the trial was not designed to study them specifically. What I can say from clinical work with founders post-retreat is that the pattern the trial captured, a relatively short structured intervention that produces durable change at 32 weeks, does show up in this population, particularly when the drinking has been used as a coping pattern around chronic work stress rather than as the primary problem. The complication is that clinical AUD screens like the AUDIT miss many high-functioning drinkers because the questions emphasize functional impairment that successful executives do not yet show. Treatment can be delayed for years while the pattern entrenches.
The proposed mechanism has three components. First, psilocybin acts as a 5-HT2A receptor agonist on cortical pyramidal neurons, producing acute default mode network suppression that loosens the rigid self-narratives in which drinking is embedded. Second, the post-session BDNF and TrkB signaling cascade opens a two-to-four-week window of elevated cortical plasticity, during which new behavioral patterns can consolidate with biological support that is not present at baseline. Third, the subjective experience often produces meaning-making about drinking patterns, including insight into what the drinking has been doing for the person emotionally, which sets up the integration work. None of these mechanisms are alcohol-specific, which is part of why psilocybin shows effects across multiple substance use disorders, tobacco, alcohol, and opioids in early trials. The convergence of plasticity, narrative shift, and behavioral change in the same window is what makes the effect size unusual.
Active heavy drinking and recent unmedicated detox are both contraindications for psychedelic-assisted work, for different reasons. Active heavy drinking interferes with neurotransmitter systems and increases the risk of dysregulated arousal during the session. Recent unmedicated alcohol detox carries seizure risk that does not mix safely with the autonomic activation of a psychedelic experience. The Bogenschutz 2022 protocol required a minimum period of stable medical supervision and screening before the first psilocybin session, and most legitimate programs follow similar guardrails. In practice, this means working with a physician on a structured taper or medically supervised detox first, achieving a baseline of stable abstinence or significantly reduced use, addressing any comorbid liver or cardiac issues, and only then beginning psychedelic-assisted work. Skipping these steps in the name of urgency is one of the more common ways the work becomes harmful rather than helpful.